Bridges Investment Management Inc. Raises Stock Holdings in Merck & Co., Inc. (NYSE:MRK)

Bridges Investment Management Inc. lifted its holdings in shares of Merck & Co., Inc. (NYSE:MRKFree Report) by 3.8% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 46,763 shares of the company’s stock after purchasing an additional 1,698 shares during the quarter. Bridges Investment Management Inc.’s holdings in Merck & Co., Inc. were worth $5,098,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently modified their holdings of the business. Moneta Group Investment Advisors LLC lifted its position in Merck & Co., Inc. by 103,159.7% in the 4th quarter. Moneta Group Investment Advisors LLC now owns 39,327,490 shares of the company’s stock worth $4,363,385,000 after buying an additional 39,289,404 shares during the last quarter. Norges Bank bought a new stake in Merck & Co., Inc. in the 4th quarter worth approximately $2,736,293,000. Wellington Management Group LLP lifted its position in Merck & Co., Inc. by 6.7% in the 3rd quarter. Wellington Management Group LLP now owns 82,442,666 shares of the company’s stock worth $8,487,472,000 after buying an additional 5,196,914 shares during the last quarter. Renaissance Technologies LLC lifted its position in Merck & Co., Inc. by 2,671.4% in the 1st quarter. Renaissance Technologies LLC now owns 5,099,334 shares of the company’s stock worth $418,400,000 after buying an additional 4,915,334 shares during the last quarter. Finally, Barclays PLC lifted its position in Merck & Co., Inc. by 184.5% in the 2nd quarter. Barclays PLC now owns 7,254,914 shares of the company’s stock worth $837,144,000 after buying an additional 4,705,004 shares during the last quarter. Hedge funds and other institutional investors own 76.07% of the company’s stock.

Insider Buying and Selling

In related news, insider Joseph Romanelli sold 1,000 shares of the company’s stock in a transaction on Tuesday, February 13th. The stock was sold at an average price of $124.89, for a total value of $124,890.00. Following the sale, the insider now directly owns 19,569 shares of the company’s stock, valued at $2,443,972.41. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. In related news, insider Joseph Romanelli sold 1,000 shares of the company’s stock in a transaction on Tuesday, February 13th. The stock was sold at an average price of $124.89, for a total value of $124,890.00. Following the sale, the insider now directly owns 19,569 shares of the company’s stock, valued at $2,443,972.41. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, EVP Steven Mizell sold 50,694 shares of the company’s stock in a transaction on Friday, February 2nd. The stock was sold at an average price of $126.65, for a total value of $6,420,395.10. Following the completion of the sale, the executive vice president now directly owns 23,619 shares in the company, valued at $2,991,346.35. The disclosure for this sale can be found here. 0.20% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

A number of analysts recently weighed in on MRK shares. TheStreet downgraded Merck & Co., Inc. from a “b+” rating to a “c+” rating in a research report on Monday, March 4th. Truist Financial restated a “buy” rating and issued a $142.00 target price (up previously from $139.00) on shares of Merck & Co., Inc. in a research report on Thursday, March 28th. Cantor Fitzgerald reiterated an “overweight” rating and issued a $135.00 price objective on shares of Merck & Co., Inc. in a research report on Wednesday, March 27th. Wells Fargo & Company boosted their price objective on Merck & Co., Inc. from $130.00 to $135.00 and gave the company an “equal weight” rating in a research report on Wednesday, March 27th. Finally, UBS Group boosted their price objective on Merck & Co., Inc. from $135.00 to $148.00 and gave the company a “buy” rating in a research report on Friday, February 2nd. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating, ten have given a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $129.71.

Check Out Our Latest Research Report on MRK

Merck & Co., Inc. Trading Up 1.3 %

Shares of Merck & Co., Inc. stock traded up $1.67 during midday trading on Wednesday, reaching $132.02. 1,485,138 shares of the company’s stock traded hands, compared to its average volume of 8,600,913. The company has a debt-to-equity ratio of 0.89, a quick ratio of 1.00 and a current ratio of 1.25. The company has a market cap of $334.36 billion, a PE ratio of 931.07, a price-to-earnings-growth ratio of 0.52 and a beta of 0.38. The stock has a 50 day moving average of $125.45 and a 200-day moving average of $113.20. Merck & Co., Inc. has a 12 month low of $99.14 and a 12 month high of $133.10.

Merck & Co., Inc. (NYSE:MRKGet Free Report) last announced its earnings results on Thursday, February 1st. The company reported $0.03 EPS for the quarter, beating analysts’ consensus estimates of ($0.09) by $0.12. The company had revenue of $14.63 billion during the quarter, compared to the consensus estimate of $14.49 billion. Merck & Co., Inc. had a return on equity of 9.33% and a net margin of 0.61%. The firm’s revenue for the quarter was up 5.8% on a year-over-year basis. During the same quarter in the prior year, the company earned $1.62 earnings per share. As a group, equities analysts expect that Merck & Co., Inc. will post 8.59 EPS for the current fiscal year.

Merck & Co., Inc. Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, April 5th. Investors of record on Friday, March 15th will be paid a $0.77 dividend. The ex-dividend date of this dividend is Thursday, March 14th. This represents a $3.08 annualized dividend and a yield of 2.33%. Merck & Co., Inc.’s payout ratio is 2,200.00%.

Merck & Co., Inc. Company Profile

(Free Report)

Merck & Co, Inc operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes under the Keytruda, Bridion, Adempas, Lagevrio, Belsomra, Simponi, and Januvia brands, as well as vaccine products consisting of preventive pediatric, adolescent, and adult vaccines under the Gardasil/Gardasil 9, ProQuad, M-M-R II, Varivax, RotaTeq, Live Oral, Vaxneuvance, Pneumovax 23, and Vaqta names.

Featured Stories

Institutional Ownership by Quarter for Merck & Co., Inc. (NYSE:MRK)

Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.